1Hawley H B, Gump D W. Vancomycin therapy of bacterial meningitis [J]. Am J Dis Child,1973,126(2) :261-264.
2Thong M L, Puthucheary S D, Lee E L. Flavobacterium meningosepticum infection:an epidemiological study in a newbom nursery [ J ]. J Clin Pathol, 1981,34 (4) :429-433.
3Bloch K C, Nadarajah R, Jacobs R. Chryseobacterium meningosepticum:an emerging pathogen among immunocompromised adults. Report of 6 cases and literature review [ J ]. Medicine ( Baltimore ) , 1997,76 (1) :30-41.
4Husson M O, lzard D, Bouillet L,et al. Comparative in-vitro activity of ciprofloxacin against non-fermenters [ J ]. J Antimicrnb Chemother, 1985,15 (4) :457-462.
2Nulens E,Bussels B,Bols A,et al.Recurrent bacteraemia byChryseobacterium meningosepticum in an oncology patient with a totally implanted int ravascular device[J].Clin Microb Infect,2001,7 (7):391.
3Rossolini GM,Franceschini N,Lauretti L,et al.Cloning of aCnryseooactentun meningosepticum chromosomal gene encoding an extended-spectrum class A beta lactamase related to the Bacteroides cephalosporinases and the VEB-1 and PER beta lactamases.AntimicrobAgents Chemother,1999,43 (9):2193.
4Bellais S,Poirel L,Nass T,et al.Genetic biochemical analysis and distrbution of the Ambler class A beta lactamase CME-2,responsible for extended-spectrum cephalosporin resistance in Chryseobacteriummeningosepticum.Antimicrob Agents Chemother,2000,44 (1):1.
